Company Filing History:
Years Active: 2025
Title: Angela Schoch: Innovator in Antibody Research
Introduction
Angela Schoch is a prominent inventor based in Munich, Germany. She has made significant contributions to the field of antibody research, particularly in understanding the interactions that influence the in vivo half-life of antibodies. Her innovative work has led to the development of a patented method that enhances the efficiency of antibody therapies.
Latest Patents
Angela Schoch holds a patent titled "Vitro prediction of in vivo half-life." This patent describes a method for determining the presence of antibody-Fab-FcRn interaction in an antibody-Fc-FcRn complex. The method involves determining the retention time of the antibody on an FcRn affinity chromatography column under varying sodium chloride concentrations. The results of this method can significantly impact the development of more effective antibody therapies.
Career Highlights
Angela is currently employed at Hoffmann-La Roche Inc., a leading company in the pharmaceutical industry. Her work at this esteemed organization allows her to collaborate with other experts in the field and contribute to groundbreaking research. Angela's dedication to her work is evident in her innovative approach to solving complex problems in antibody interactions.
Collaborations
Angela has worked alongside notable colleagues such as Thomas Emrich and Hubert Kettenberger. Their collaborative efforts have further advanced the research in antibody therapies and have contributed to the success of their projects.
Conclusion
Angela Schoch is a remarkable inventor whose work in antibody research has the potential to transform therapeutic approaches. Her patented method for predicting in vivo half-life is a testament to her innovative spirit and dedication to advancing medical science.